We are on a global mission to establish ocular gene therapy as a one-time treatment that preserves patient sight for life.
learn more
Adverum Announces Shortened Timelines and Clear Development Path for ADVM-022 Intravitreal Gene Therapy in Wet AMD, Reports Recent Business Progress and Fourth Quarter 2020 Financial Results
Adverum to Host Conference Call and Webcast to Highlight Updated ADVM-022 Development Plans in Wet AMD, Recent Business Progress, and Fourth Quarter 2020 Financial Results
Adverum Appoints Esteemed Healthcare Executive Reed V. Tuckson, M.D., to Board of Directors